China Kanghui Holdings Considered A Capable Contender
China Kanghui Holdings (NYSE: KH) has outperformed the S&P since its IPO in August (+20% vs. +3.4%) showing healthy investor interest in the Chinese orthopedics market, according to Piper Jaffray.
KH separates itself from its competitors by implementing a well-assembled management team and its access to technology, and KH is expected to post an EPS CAGR of 22% from 2009-2015, driven by its new product launches and market share gains, Piper Jaffray reports.
Piper Jaffray initiates with a Neutral rating and $14 price target.
China Kanghui Holdings closed Friday at $12.33.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.